EMA Authorised: Mycophenolate mofetil Teva (mycophenolate mofetil) — Teva Pharma B.V.

View source ↗

Summary

The European Medicines Agency authorised Teva's generic mycophenolate mofetil product for preventing organ transplant rejection, with decision dated 26 March 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Organ Transplant Rejection

Drugs mentioned

• Mycophenolate mofetil Teva (mycophenolate mofetil)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Teva Pharma B.V.. Decision date: 26/03/2026